Tag Archives: BAN2401

October, 2018

July, 2018

December, 2017

  • 21 December

    Eisai and Biogen’s Alzheimer’s Disease Drug Fails in Mid-Stage Trial

    CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that an Independent Data Monitoring Committee has determined that BAN2401, an anti-amyloid beta protofibril antibody, did not meet the criteria for …